

## Aptamer-based microfluidic electrochemical biosensor for monitoring cell-secreted trace cardiac biomarkers

SuRyon Shin, Yu Shrike Zhang, Duckjin Kim, Ahmad Manbohi, Huseyin Avci, Antonia Silvestri, Julio Aleman, Ning Hu, TUGBA KILIC, Wendy Keung, Martina Righi, Pip Assawes, Hani A. Alhadrami, Ronald A. Li, Mehmet R. Dokmeci, and Ali Khademhosseini

*Anal. Chem.*, **Just Accepted Manuscript** • DOI: 10.1021/acs.analchem.6b02028 • Publication Date (Web): 12 Sep 2016

Downloaded from <http://pubs.acs.org> on September 14, 2016

### Just Accepted

"Just Accepted" manuscripts have been peer-reviewed and accepted for publication. They are posted online prior to technical editing, formatting for publication and author proofing. The American Chemical Society provides "Just Accepted" as a free service to the research community to expedite the dissemination of scientific material as soon as possible after acceptance. "Just Accepted" manuscripts appear in full in PDF format accompanied by an HTML abstract. "Just Accepted" manuscripts have been fully peer reviewed, but should not be considered the official version of record. They are accessible to all readers and citable by the Digital Object Identifier (DOI®). "Just Accepted" is an optional service offered to authors. Therefore, the "Just Accepted" Web site may not include all articles that will be published in the journal. After a manuscript is technically edited and formatted, it will be removed from the "Just Accepted" Web site and published as an ASAP article. Note that technical editing may introduce minor changes to the manuscript text and/or graphics which could affect content, and all legal disclaimers and ethical guidelines that apply to the journal pertain. ACS cannot be held responsible for errors or consequences arising from the use of information contained in these "Just Accepted" manuscripts.



**Aptamer-based microfluidic electrochemical biosensor for monitoring cell-secreted trace cardiac biomarkers**

Su Ryon Shin<sup>a,b,c,#</sup>, Yu Shrike Zhang<sup>a,b,c,#</sup>, Duck-Jin Kim<sup>a,b,#</sup>, Ahmad Manbohi<sup>a,b,d</sup>, Huseyin Avci<sup>a,b,e</sup>,  
Antonia Silvestri<sup>a,b,h</sup>, Julio Aleman<sup>a,b</sup>, Ning Hu<sup>a,b,f</sup>, Tugba Kilic<sup>a,b,g</sup>, Wendy Keung<sup>i</sup>, Martina Righi<sup>a,b,j</sup>,  
Pip Assawes<sup>a,b</sup>, Hani A. Alhadrami<sup>k,m</sup>, Ronald A. Li<sup>i</sup>, Mehmet R. Dokmeci<sup>a,b,c</sup>, Ali  
Khademhosseini<sup>a,b,c,n,o\*</sup>

<sup>a</sup>Biomaterials Innovation Research Center, Division of Biomedical Engineering, Department of  
Medicine, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA 02139, USA.

<sup>b</sup>Harvard-MIT Division of Health Sciences and Technology, Massachusetts Institute of Technology,  
Cambridge, MA 02139, USA.

<sup>c</sup>Wyss Institute for Biologically Inspired Engineering, Harvard University, Boston, MA 02115, USA.

<sup>d</sup>Chemistry & Chemical Engineering Research Center of Iran, P.O. Box 14334-186, Tehran, Iran.

<sup>e</sup>Eskisehir Osmangazi University, Faculty of Engineering and Architecture, Metallurgical and Materials  
Engineering Department, Eskisehir, Turkey.

<sup>f</sup>Biosensor National Special Laboratory, Key Laboratory of Biomedical Engineering of Ministry of  
Education, Department of Biomedical Engineering, Zhejiang University, Hangzhou, Zhejiang 310027,  
PR China.

<sup>g</sup>Izmir Katip Celebi University, Faculty of Engineering and Architecture, Department of Biomedical  
Engineering, Izmir, Turkey.

<sup>h</sup>Politecnico di Torino – Department of Electronics and Telecommunications (DET), Corso Duca degli  
Abruzzi 24, 10129, Torino, Italy.

<sup>i</sup>Stem Cell and Regenerative Medicine Consortium, LKS Faculty of Medicine, University of Hong Kong, Hong Kong.

<sup>j</sup>The BioRobotics Institute, Scuola Superiore Sant'Anna, Viale Rinaldo Piaggio 34, 56025 Pontedera (PI), Italy.

<sup>k</sup>Faculty of Applied Medical Sciences, Department of Medical Technology, King Abdulaziz University, Jeddah, 21589, Kingdom of Saudi Arabia.

<sup>m</sup>Center of Innovation in Personalized Medicine, King Fahd Medical Research Center, King Abdulaziz University, Jeddah, 21589, Kingdom of Saudi Arabia.

<sup>n</sup>Department of Physics, King Abdulaziz University, Jeddah 21569, Saudi Arabia.

<sup>o</sup>College of Animal Bioscience and Technology, Department of Bioindustrial Technologies, Konkuk University, Hwayang-dong, Kwangjin-gu, Seoul, Republic of Korea.

## CORRESPONDING AUTHOR

Biomaterials Innovation Research Center, Division of Biomedical Engineering, Department of Medicine, Brigham and Women's Hospital, Boston, MA 02139, USA.

E-mail address: [alik@bwh.harvard.edu](mailto:alik@bwh.harvard.edu) (A. Khademhosseini)

<sup>#</sup> These authors contributed equally to this work.

**Abstract**

Continual monitoring of secreted biomarkers from organ-on-chip models is desired to understand their responses to drug exposure in a non-invasive manner. To achieve this goal, analytical methods capable of monitoring trace amounts of secreted biomarkers are of particular interest. However, a majority of existing biosensing techniques suffer from limited sensitivity, selectivity, stability, and require large working volumes, especially when cell culture medium is involved, which usually contains a plethora of nonspecific binding proteins and interfering compounds. Hence, novel analytical platforms are needed to provide noninvasive, accurate information on the status of organoids at low working volumes. Here, we report a novel microfluidic aptamer-based electrochemical biosensing platform for monitoring damage to cardiac organoids. The system is scalable, low-cost, and compatible with microfluidic platforms easing its integration with microfluidic bioreactors. To create the CK-MB biosensor, the microelectrode was functionalized with aptamers that are specific to creatine kinase (CK)-MB biomarker secreted from a damaged cardiac tissue. Compared with antibody-based sensors, the proposed aptamer-based system was highly sensitive, selective, and stable. The sensing performance was assessed against a heart-on-a-chip system constructed from human embryonic stem cell-derived cardiomyocytes following exposure to a cardiotoxic drug, doxorubicin. The aptamer-based biosensor was capable of measuring trace amounts of CK-MB secreted by the cardiac organoids upon drug treatments in a dose-dependent manner, which was in agreement with the beating behavior and cell viability analyses. We believe that, our microfluidic electrochemical biosensor based on aptamer-capturing mechanism will find widespread applications in integration with organ-on-chip platforms for *in situ* detection of biomarkers at low abundance and high sensitivity.

**KEYWORDS:** Heart-on-a-chip, Cardiac spheroid, Aptamer, Electrochemical biosensor, Microfluidics.

## Introduction

Drug development is a lengthy and costly process associated with high incidences of attrition<sup>1,2</sup>. In addition, roughly 20% of drugs in the past four decades have been recalled due to cardiotoxicity and other cardiac safety issues<sup>3,4</sup>. To solve this problem, human cell-based three-dimensional (3D) tissue/organ models that can precisely recapitulate the important architecture and functionality of their *in vivo* counterparts as viable platforms for drug screening prior to clinical trials have been developed<sup>5,6</sup>. These physiologically relevant human organ models have shown several major advantages over conventional animal models such as more accurate prediction of human responses<sup>6,7</sup>. Furthermore, recent developments in microfluidics have offered new approaches to fabricate biomimetic human organoid models that simulate both the biology and the physiological microenvironment of the human system, termed organs-on-chips<sup>8-10</sup>. Despite recent advances in organs-on-a-chip systems, it is difficult to obtain information about secreted biomarkers that correlate with the behavior and status of these organoids during long-term culture. For example, it is well known that the cardiac cells may remain viable yet tend to lose their metabolic activity within a few days<sup>11</sup>. Hence, it is critical to develop methods to probe (disease) biomarker secretion by the cells during continual culture or drug screening processes. In addition, the small medium volumes in these organs-on-a-chip platforms mandate that the sensing systems should consume very little sample fluids, be able to be multiplexed (i.e. can monitor multiple biomarkers), noninvasive to the organoids, and amenable to microfluidic devices allowing for seamless integration with organ constructs.

Measurement of secreted biomarkers by the organoids has been one of the approaches to assess the bioactivity and viability of the organoids in a non-invasive manner. Several detection methods have thus been utilized for label-free biosensing of secreted molecules such as those based on enzyme linked immunosorbent assays (ELISA)<sup>12</sup> and surface plasmon resonance (SPR)<sup>13</sup>, among others<sup>14</sup>. However, most of these existing techniques suffer from limited sensitivity and selectivity, especially when complex biological environments such as cell culture medium is involved, which usually contains a

1 plethora of nonspecific proteins and interfering compounds but trace amounts of biomarkers of interest.  
2  
3 The low abundance of secreted biomarkers is of critical concern particularly when it comes to disease  
4  
5 markers such as those specific for cardiac damage or injury including creatine kinase (CK)-MB ( $< 1 \text{ ng}$   
6  
7  $\text{mL}^{-1}$ ) and troponins<sup>15,16</sup>. The current gold standard for such measurements relies on ELISA, which is  
8  
9 typically insufficient in sensitivity in addition to the needs for off-chip operations that consume  
10  
11 significant sample volumes. Therefore, a robust biosensor platform featuring high sensitivity and  
12  
13 selectivity is in urgent need for probing cell behaviors in microphysiometry systems. To this end,  
14  
15 electrochemical impedance spectroscopy (EIS) with high sensitivity and ultra low limit-of-detection  
16  
17 (LOD) at low cost has numerous advantages compared to other biosensing techniques. Moreover,  
18  
19 electrochemical biosensors are compatible with microfluidics technologies, allowing for facile  
20  
21 integration with microfluidic organs-on-a-chip platforms for continual monitoring of (multiple) secreted  
22  
23 biomolecules in a noninvasive manner while consuming only small volumes of media<sup>17,18</sup>.

24  
25  
26 To improve the selectivity and stability along with high sensitivity of a biosensor operating  
27  
28 within complex biological environments such as cell culture medium, aptamers, which are nucleic acids  
29  
30 with meticulously designed sequences, have been widely employed as the sensitive recognition  
31  
32 elements of biosensors for the detection and quantification of various analytes such as nucleic acid,  
33  
34 proteins, and cells<sup>19-26</sup>. In comparison to antibodies, aptamers seldom aggregate, facilitating their  
35  
36 uniform deposition over the sensing surfaces<sup>27,28</sup>. In addition, they can easily be chemically modified  
37  
38 with functional groups to provide them with tailored properties<sup>29,30</sup>. Furthermore, the sensitivity and  
39  
40 selectivity of aptamers are relatively stable with respect to disturbances such as changes in pH,  
41  
42 temperature, and interferents over lengthy periods. Therefore, to measure low levels of soluble  
43  
44 biomarkers, aptamers are excellent candidates as a class of receptors for use in an electrochemical  
45  
46 biosensing platform compared to conventional antibodies, where higher sensitivity has been reported for  
47  
48 aptamer-based electrochemical immunosensors<sup>31</sup>.

49  
50 Here we report the development of an aptamer-based electrochemical biosensor that can be  
51  
52 integrated with a microfluidic platform for in-line detection of secreted protein biomarkers from organ-  
53  
54  
55  
56  
57  
58  
59  
60

on-chip devices. In particular, the sensor was functionalized with aptamers specific to a cardiac injury biomarker in extremely low abundance, CK-MB. This aptamer-based electrochemical biosensor was analyzed for its sensitivity and compared with antibody-based immunosensors. Their performances were further assessed in conjunction with a microfluidic heart-on-a-chip system constructed from human embryonic stem cell-derived cardiomyocytes (ESC-CMs). The trace changes in the ( $< 1 \text{ ng mL}^{-1}$ ) secreted CK-MB levels by the cardiac organoids upon drug insults in a dose-dependent manner were measured by the aptamer-based electrochemical immunosensors, and compared to other organoid evaluation methods including beating rates and cellular viability. The developed system is versatile and can be used to detect various cell-secreted biomarkers.

## Results and Discussion

To monitor secreted CK-MB levels, EIS measurements were utilized. A microelectrode set having a reference electrode (RE), a counter electrode (CE), and a working electrode (WE) was custom designed and fabricated (Figure 1(a)), for convenient integration with a microfluidic sensing platform. To achieve a stable biosensing system, Au was chosen as the electrode material since it has numerous advantages including favorable electron transfer kinetics, relatively good stability, and convenient covalent bonding with functional groups such as thiol-containing molecules (through the formation of gold (Au)-S bonds)<sup>32,33</sup>. The metal layers were deposited using an electron beam deposition process where a shadow mask was adopted for patterning. The Au CE and WE were deposited on top of a titanium (Ti) seed layer (20 nm), where a palladium (Pd) layer with a thickness of 20 nm was sandwiched in between two layers, to block the diffusion of Ti into the Au layer during the annealing procedure (300 °C for 6 hrs in the furnace).

We then developed an on-chip process for attaching antibodies and aptamers onto the surface of the Au electrodes based on a combination of the Au-S bonding mechanism, the carbodiimide chemistry, and the streptavidin-biotin reactions<sup>34</sup>. Figure 1(b) shows schematic illustration of the immobilization steps of aptamers onto the Au surface. In the first step, the Au surface was functionalized by

immobilizing a self-assembling monolayer (SAM) from spacers containing thiol groups on one end and carboxyl groups on the other terminal. The creation of a covalent bonding between SAM (exposed carboxyl groups) and amine-terminated aptamers was then achieved through the N-ethylcarbodiimide (EDC)/N-hydroxysuccinimide (NHS)-based carbodiimide chemistry. Functionalization of antibodies was similar, except for one additional step, i.e. streptavidin-amine was subsequently attached to the SAM layer using carbodiimide chemistry followed by grafting of the biotinylated antibodies *via* the streptavidin-biotin interaction. These processes are simple and efficient, allowing for functionalization of the Au electrodes with antibodies/aptamers in a highly reproducible manner.

To investigate the variations on the Au electrode surface before and after functionalization with antibodies/aptamers, the atomic force microscopy (AFM) analysis was performed (Figure 1 (c) – (e)). The surface roughness of the bare electrodes obtained from AFM measurements was 1.79 nm as shown in Figure 1(c). The surface roughness of the electrodes functionalized with aptamers and antibodies was found to increase to 2.75 nm and 2.53 nm, respectively. The covalent immobilization method led to a relatively uniform distribution of the aptamers and antibodies on the surface of the electrodes (Figure 1(d) and (e)). Successful functionalization of each antibody/aptamer layer on bare electrodes was confirmed by a subsequent increase in the impedance signal obtained after the deposition of the each layer (Figure 1(f) and Figure S1). The Nyquist plot obtained from the bare electrodes was almost a straight line, which was characteristic of a diffusion-limiting process (Figure 1(f)-inset). However, a significant semicircle curve appeared in the high frequency region after immobilization of the SAM layers on the electrode. The  $R_{ct}$  increased to  $\sim 2 \text{ M}\Omega$ , indicating that electron transfer between  $[\text{Fe}(\text{CN})_6]^{3-/4-}$  and the electrode was strongly blocked by the SAM layers on the electrode<sup>35</sup>. In addition, the  $R_{ct}$  value obtained from the Au electrode after immobilization of the SAM was larger than the value obtained from the SAM functionalized Au electrodes reported previously<sup>36,37</sup>. We believe that this discrepancy was due to the smaller surface area of our WE ( $\sim 0.5 \text{ mm}^2$ ) compared to that of previously reported Au disk electrodes ( $\sim 8.0 \text{ mm}^2$ )<sup>36,38</sup>.

## Shelf-life and selectivity of the electrochemical biosensors

The shelf-life of the biosensor is an important factor during monitoring of biomarkers. To investigate the shelf-life of the aptamer and antibody-based biosensors, the two devices were stored under moderately wet conditions at 4 °C since the biosensors will be exposed to prolonged wet conditions during real sample analysis. We prepared both biosensors on the same day and stored them for different time periods in PBS at 4 °C before they were used to measure CK-MB levels (1 ng mL<sup>-1</sup>). As shown in Figure 1(g), the normalized  $\Delta R_{ct}$  values obtained from the aptamer-based biosensors showed relatively shelf-life for up to 7 days of storage. In comparison, the normalized  $\Delta R_{ct}$  values obtained from antibody-coated biosensors decreased dramatically (~ 60%) over the same period of time. These results clearly indicate that the aptamer-based biosensors had a much longer shelf-life compared to antibody-functionalized electrodes likely due to the easy denaturation of the protein-based antibodies. The improved shelf-life of the aptamer biosensors also potentially enable their use in monitoring of biomarkers over extended periods of time.

For applications in complex biological environments such as cell culture medium containing a large amount of proteins (bovine serum albumin (BSA)) and other small molecules, the aptamer based biosensor should be selective only towards CK-MB antigens. To prevent non-specific binding of proteins to surfaces of electrode, we used cell culture medium as the blocking agent instead of conventional blocking agents such as BSA. When we blocked the aptamer-functionalized electrode surface only by BSA, the impedance changed after incubation with the culture medium for human embryonic stem cell-derived cardiomyocytes even without the CK-MB antigen. This cell culture medium is composed of various materials such as BSA, L-glutamine, insulin, and vitamin A, etc. In particular, those components with smaller molecular weights such as L-glutamine, insulin, and vitamin A might penetrate into the BSA blocking layer on aptamer-functionalized electrode. These incorporated molecules within the BSA blocking layer might induce an impedance change after incubation compared with the pristine BSA blocking layer. Therefore, we used the cell culture medium as the blocking agent

and then optimized the incubation time to block the electrode after immobilization of aptamers using the cell culture medium, which did lead to a large increase in the impedance signal. However, the 30-min incubation was sufficient to block the surface of electrode since we observed that the incubation period exceeding 30 min did not significantly change the impedance of the electrodes anymore (data not shown). In an ideal setting, neither the medium itself (i.e. ions) nor the proteins and small molecules should interfere with CK-MB sensing. In an ideal setting, neither the medium itself (i.e. ions) nor the proteins and small molecules should interfere with CK-MB sensing. The selectivity of the aptamer-based biosensors was evaluated against other biomarkers, including 10 ng mL<sup>-1</sup> albumin and glutathione S-transferase alpha (GST- $\alpha$ ) that are well-known liver biomarkers, both for 30 min. The results in Figure S2 demonstrated that, after exposure to these antigens, the impedance measured from the electrodes did not show significant changes, revealing that non-specific binding did not occur during the incubation of the biosensor with albumin and GST- $\alpha$  antigens. However, subsequent addition of 10 ng mL<sup>-1</sup> CK-MB was found to result in a significant increase in the impedance as observed in Figure S2. These data confirmed that the developed aptamer immunosensor had good selective detection for CK-MB, leading to aptamer-target interaction.

### Sensitivities of the biosensors

We next evaluated the sensitivity of both types of biosensors. After incubation of the biosensors with different concentrations of CK-MB antigens, the EIS measurements were obtained at each antigen concentration (Figure 2(a) and (b)). To eliminate any possible individual variation of physical and electrochemical difference that may be present among the different electrodes, we determined normalized  $\Delta R_{ct}$  via dividing the  $R_{ct}$  of CK-MB (or any biomarker) by the  $R_{ct}$  of media, which is termed “As-prepared” signal, and was used as the baseline of the biosensors. The standard curves were next obtained by plotting normalized  $\Delta R_{ct}$  at a range of concentrations (0.01-100 ng mL<sup>-1</sup>) in both PBS and culture media. As shown in Figure 2(c) and (d)), the aptamer-based biosensor was found to be more

sensitive than the antibody-based biosensor in measuring CK-MB levels in both PBS and medium. The slope of the calibration curves for CK-MB antigens prepared in PBS and medium measured by the aptamer-based biosensors were 0.48 and 0.33, respectively, while these values measured using antibody-based biosensors were 0.30 and 0.26, respectively. Therefore, the sensitivities of aptamer-based biosensors for CK-MB measurements were 1.58 and 1.26 times higher those of antibody-based biosensors in PBS and medium, respectively. However, the reduced sensitivity for both aptamer- and antibody-based biosensors in the cell culture medium was likely associated with the interference of non-specific protein ( $\sim 99 \text{ mg mL}^{-1}$  BSA) or small molecules surrounding the minute concentration of CK-MB antigen in the culture medium compared to the much less complex environment of PBS. These results indicated that the aptamers coated onto the microelectrodes could be efficiently used to detect CK-MB in a complex microenvironment at a high sensitivity with a LOD of  $2.4 \text{ pg mL}^{-1}$  and a wide dynamic range ( $0.01\text{--}100 \text{ ng mL}^{-1}$ ). This LOD obtained from the aptamer-based electrochemical biosensor for CK-MB detection is lower than those obtained by other similar EIS detection methods that used an Au electrode array ( $10 \text{ pg mL}^{-1}$ )<sup>39</sup> or other methods including immunochemiluminometric assay ( $\sim 1 \text{ ng mL}^{-1}$ )<sup>40,41</sup>, amperometric assay ( $0.11 \text{ } \mu\text{g mL}^{-1}$ )<sup>42</sup>, capillary immunoassay ( $0.6 \text{ ng mL}^{-1}$ )<sup>43</sup>, SERS-based ELISA ( $42.5 \text{ pg mL}^{-1}$ )<sup>44</sup>, antibody-based SPR sensors ( $2.71 \text{ ng mL}^{-1}$ )<sup>45</sup>, and slightly lower than that of silicon nanowire field-effect transistor-based biosensor (SiNW-FET) ( $100 \text{ fg mL}^{-1}$ ) due to field-effect amplification of the FETs<sup>46</sup>. However, the fabrication of SiNW-FETs is complex and expensive, while our EIS detection method based on aptamers is sufficiently sensitive with a wide detection range for the cardiac biomarker, CK-MB. In addition, continual increase in impedance signals were observed in all cases (Figure 2(c) and (d)), suggesting that even high concentrations of up to  $100 \text{ ng mL}^{-1}$  of CK-MB did not result in the saturation of the electrodes. Therefore, after a minute amount of CK-MB is captured on the electrode surface, there is a potential to continue using these electrodes for multiple times before saturation.

Overall, aptamer-based biosensors possess several key advantages for measuring biomarkers in complex environments such as the culture medium, compared with antibody-based biosensors. The

aptamer-based biosensors have ultrahigh sensitivity on the order of a few  $\text{pg mL}^{-1}$ . Furthermore, the shelf life of aptamer-based biosensors was found to be at least 7 days, which may potentially be extended to several weeks and even months when frozen due to the stability of the aptamers. In comparison, antibody-based biosensors appeared to have a lower shelf-life, which significantly limits their ease of use. It is also expected that aptamers can endure harsh conditions such as extreme pH, while antibodies will only operate under near physiological conditions<sup>31,47,48</sup>. Based on these observations, aptamer-based biosensors can function as an excellent biosensing platform to monitor extremely low concentrations of CK-MB produced by heart-on-a-chip systems.

### Heart-on-chip and cardiotoxicity studies

Development of biomimetic heart-on-a-chip systems offers new insights to monitor cardiac functions for quantitative exploration of drug-induced cardiotoxicity<sup>49,50</sup>. Noninvasive continuous measurement of cellular metabolic activity is needed to probe the activity of drugs on such models. Measurement of cardiac organoid functionality has conventionally been carried out by optical and electrophysiological approaches that observe the physical contraction of the cardiac organoids and detect the action potential of the cardiomyocytes<sup>51,52</sup>. To date, there have only been a few reports in determining the functionality of heart-on-a-chip systems that have utilized biomolecular sensing<sup>53,54</sup>. Moreover, cardiac injury/damage biomarkers such as CK-MB, myosin, and troponins are expressed at low levels by the cardiomyocytes upon exposure to toxic agents, which are highly diagnostic and predictive of cardiac damage<sup>16</sup>. Hence, a detection platform that can be directly integrated with a heart-on-a-chip system for real time or near real time monitoring of secreted cardiac biomarkers for cardiotoxicity assessment is of great importance.

A cardiac bioreactor was constructed by modifying our recently published protocols (Figure 3(a))<sup>55</sup>. Cardiac spheroids (~200  $\mu\text{m}$  in diameter) derived from ESC-CMs were embedded inside a gelatin methacryloyl (GelMA) hydrogel, dispensed, and photocrosslinked at the bottom of the bioreactor to

1 generate the human cell-based heart-on-chip platform (Figure 3(a), inset). The cardiac spheroids were  
2 successfully cultured for up to 5 days in the bioreactors without leakage or contamination. Doxorubicin  
3 (DOX), an anticancer drug, was used as the model drug to induce cardiac injury in the cardiac spheroids.  
4  
5 The exposure of cardiomyocytes to DOX is expected to increase the levels of secreted CK-MB antigens  
6  
7 by the cardiomyocytes and result in changes in their beating rates<sup>56,57</sup>. Indeed, Figure 3(b) indicates that  
8  
9 the relative beating rates of the cardiomyocytes in the heart-on-chips significantly decreased over time  
10  
11 after the cells were exposed to DOX, resulting in reduced beating rates of 85% and 82% corresponding  
12  
13 to drug concentrations of 1  $\mu\text{M}$  and 10  $\mu\text{M}$ , respectively. The viability of the cardiomyocytes was  
14  
15 further analyzed using a live/dead assay. As shown in Figure 3(c), while the cells in the control  
16  
17 condition (no drug) exhibited high cell viability at all time points. The cells that were treated with drugs  
18  
19 had a decrease in their viability over a period of 5 days, especially in the group where 10  $\mu\text{M}$  DOX was  
20  
21 used. The changes in beating rates and the viability assessment of the heart-on-chip system confirmed  
22  
23 the capability of DOX to induce cardiotoxicity in the *in vitro* cardiac model.  
24  
25  
26  
27  
28  
29  
30

31 It is further expected that the amount of CK-MB in the media collected from the cardiac  
32  
33 bioreactors should also increase over time as the cardiomyocytes undergo damage upon exposure to the  
34  
35 drug. To evaluate the response of the cardiac organoids to DOX, the CK-MB biosensor was utilized to  
36  
37 measure the CK-MB levels in bioreactors administered with 0, 1, and 10  $\mu\text{M}$  DOX after 6, 30, 78, and  
38  
39 126 hrs. For these tests, the CK-MB specific aptamer-based biosensor was incubated with bioreactor  
40  
41 samples for 30 min and then the EIS was measured (Figure 4(a)). The normalized  $\Delta R_{\text{ct}}$  data obtained  
42  
43 from the EIS measurements were correlated to the concentrations of CK-MB using a calibration curve  
44  
45 (Figure 4(b)). The concentrations of secreted CK-MB antigens remained at negligible levels in cardiac  
46  
47 bioreactors with no drug treatment throughout the entire period. However, administration of 1  $\mu\text{M}$  and  
48  
49 10  $\mu\text{M}$  DOX induced significant cell damage resulting in an increase in CK-MB levels in both dose- and  
50  
51 time-dependent manner, clearly indicating the cytotoxic effect of DOX towards the cardiomyocytes.  
52  
53 The concentrations of CK-MB in the media retrieved from the cardiac bioreactors after 30, 78, and 126  
54  
55 hrs were measured to be 24, 80 and 120  $\text{pg mL}^{-1} \text{ cell}^{-1}$ , respectively, after 1  $\mu\text{M}$  DOX treatment, while  
56  
57  
58  
59  
60

the group treated with a 10  $\mu\text{M}$  DOX reached 45, 115, and 149  $\text{pg mL}^{-1} \text{ cell}^{-1}$  (Figure 4(b)). Comparing the beating behavior and cellular viability in Figure 3(b) and (c), it can be concluded that the DOX treatment of cardiomyocytes influenced the cells in a dose-dependent manner where higher doses of DOX reduced the beating rates as well as the cellular viability. In addition, we have also observed that higher DOX concentrations resulted in elevated levels of CK-MB secretion from the cardiac organoids. This was expected since the CK-MB is known to be a myocyte injury biomarker<sup>58</sup>.

After confirming that our aptamer-based biosensor could successfully measure trace amounts of CK-MB present in the media following cardiac damage caused by the drug, the sensor chip was further integrated with a heart-on-a-chip platform for *in situ* monitoring (Figure 4(c)). Installation of the microfluidic and sensing modules into the portable incubator allowed ease of use and automated handling of the integrated system. It also protected the vulnerable or sensitive components of the biosensor from potential damage or contamination. This chip was built from polydimethylsiloxane (PDMS) using soft lithography, which possessed a fluid loop for medium circulation and sampling, 2 inlets for electrolyte injection and washing, 1 chamber hosting the electrode, and 1 common outlet (Figure 4(d)). The microfluidic chip consisted of three layers including a fluidic layer, a valve layer, and a thin-membrane in between. Each channel was controlled by a pneumatic valve *via*  $\text{N}_2$  gas pressure. To visually distinguish the valve layer from the microfluidic layer and prevent the diffusion of gas to the fluidic channel, the valve channels were filled with food dye (green color in Figure 4(d)). The medium from the cardiac bioreactor was sampled at pre-determined time points for biomarkers measurements which were conducted later on by the microfluidic biosensor. The medium in the organ modules was driven by a peristaltic pump, while the liquid handling of the reagents for electrochemical sensing was conducted by externally actuated pneumatic valves programmed to operate in an automated manner. This microfluidic chip required approximately 9  $\mu\text{l}$  of sample volume. The concentrations of CK-MB levels secreted by the cardiac organoids upon treatment of different concentrations of DOX after 6, 30, 78, and 126 hrs were then calculated from  $\Delta R_{\text{ct}}$  values (Figure 4(e) and (f)). Similar to off-line results, on-chip measurements (heart-on-chip platform) also revealed a similar trend, where higher levels of

1 CK-MB antigens were detected, which corresponded to the use of higher concentrations of DOX and  
2 longer exposure times. These results clearly demonstrated that our aptamer-based electrochemical  
3 biosensor can be integrated with microfluidic organs-on-a-chip platforms and can be used for *in situ*,  
4 continual measurement of biomarkers till the saturation point of cell-secreted biomarkers. We also  
5 demonstrated that trace amounts of biomarkers ( $\text{pg mL}^{-1}$ ) can be readily detected with high sensitivity.  
6 This is the first time that an integrated sensor was used to directly obtain cell-secreted biomarkers from  
7 a cardiac-organoid-on-a-chip system for rapid detection without any delays or off-chip processing. This  
8 critical feature of our aptamer-based biosensors can be conveniently expanded to other organ models  
9 where the detection of trace amounts of (damage) biomarkers is desired.  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23

## 24 Conclusions

25  
26 In this paper we have developed a novel integrated label-free electrochemical biosensing  
27 platform combining an in-house designed Au microelectrode and a microfluidic system, to achieve fast  
28 and sensitive measurement of secreted biomarkers at low concentrations from a human cardiac-  
29 organoid-on-a-chip model. The use of aptamers as the antigen receptors was shown to significantly  
30 increase the sensitivity and shelf-life of the biosensor in comparison to the use of antibody-based  
31 biosensors. The biosensor functionalized with aptamers specific to cardiac damage biomarker CK-MB  
32 was then validated using samples taken from a human heart-on-a-chip model. Successful detection of  
33 trace amounts of CK-MB secreted by the cardiac organoids upon drug treatments was carried out in a  
34 dose-dependent manner. The results obtained from biosensors were in agreement with the changes in  
35 the beating rates and cellular viability assessments. We believe that, our unique microfluidic  
36 electrochemical biosensor based on the aptamer-capturing mechanism can be conveniently extended to  
37 the measurement of a wide variety of other biomarkers of interest. With further development in  
38 multiplexing and optimization, these aptamer-based microfluidic electrochemical biosensors are  
39 expected to find widespread applications in monitoring organ-on-a-chip platforms for continual *in situ*  
40 detection of biomarkers at trace amounts.  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## Experimental Methods

**Preparation of microelectrode:** The diameter of the WE was 800  $\mu\text{m}$ , the width of CE and RE were 150  $\mu\text{m}$ , and gap between WE and other two electrodes was 200  $\mu\text{m}$ , and the diameter of detection area was about 1500  $\mu\text{m}$ . The glass substrate was diced to specific dimensions using a dicing saw machine. The diced glass chips were cleaned by acetone, isopropyl alcohol, and DI water and dried at 120  $^{\circ}\text{C}$  in an oven. The shadow mask of 0.25 mm thickness with apertures was attached to the glass substrate. 20 nm-thick Ti, 20 nm-thick Pd, and 500 nm-thick Au were selectively deposited on the glass using the shadow mask by an e-beam evaporator to create the WE and CE. Then, the second shadow mask for RE patterning was attached to the Au deposited glass substrate. In the same manner, 20 nm-thick Ti, 20 nm-thick Pd and 500 nm-thick Ag were deposited on the glass substrate. Finally, the electrodes were annealed at 300  $^{\circ}\text{C}$  for 6 hrs in a furnace.

**Electrochemical measurements:** Measurements of EIS spectrum was performed using an electrochemical workstation CHI660E (CH instrument, Inc.) with a conventional three electrode system. For the EIS technique, the initial potential was set to 0.1 V and the range of frequencies were scanned from 0.1 Hz to 100 kHz at 5 mV of amplitude. All measurements were carried out in 50 mM  $\text{K}_3\text{Fe}(\text{CN})_6$  electrolyte solution.

**Fabrication of microfluidic chips:** The transparent polymer film was used as a photomask in a photolithography process on a layer of SU-8 photoresist, UV exposed area created a positive relief of channel structure. This SU-8 structure was then used as master for casting PDMS channels by replica molding. In order to create the PDMS mold, the SU-8 master was covered with a liquid PDMS prepolymer in a mixture of 1:10 base polymer: curing agent and cured in the oven at 80  $^{\circ}\text{C}$  for 1 hr. The cured PDMS mold was peeled off from the master. To prepare the thin membrane, PDMS was poured in a Petri dish and a film with a 40  $\mu\text{m}$  of thickness was formed by spin coater. Then the PDMS layer was cured at 80  $^{\circ}\text{C}$  in an oven for 1 hour. The three layers were bonded together after being treated with air

1 plasma for 70 sec where the microelectrodes were housed inside the fluidic channel. To connect the  
2 microfluidic chip to a syringe pump, metal connectors and tubes were inserted into the inlet and outlet  
3 ports. All the fluidic channels were initially filled with DPBS from the outlet to the inlet with a syringe  
4 pump at a flow rate of 1.0 ml hr<sup>-1</sup>.  
5  
6  
7  
8

9 **Immobilization process for aptamer and antibody biosensors:** After cleaning the fabricated  
10 microelectrodes, DPBS and ethanol were flowed for 7 min and 10 min, respectively. After that step, the  
11 SAM solution aimed to generate the thiol terminated SAM was flowed from a dedicated channel for 10  
12 min and incubated in the reaction chamber for 1 hr by using 11-mercaptoundecanoic acid (11-MUA).  
13 Then, the microelectrode in reaction chamber was rinsed with ethanol and DPBS subsequently for 10  
14 min and 7 min, respectively, to remove the unbound SAM molecules. The mixed solution of EDC (50  
15 mM) and NHS (50 mM) was injected into the reaction channel and incubated for 15 min to convert the  
16 activation of NHS ester, which was able to react with primary amine groups in aptamer or streptavidin  
17 by the amide bond. We obtained CK-MB 1A aptamer with a 5'Amine from OTCbiotech to specially  
18 capture CK-MB1, which had little-to-no cross-reactivity with CK-MB2. To immobilize the antibodies,  
19 10 µM streptavidin solution was flowed for 7 min to the reaction chamber and incubated for 1 hr after  
20 incubation of the NHS/EDC solution. Then, a 10 µM biotinylated antibody solution was flowed for 7  
21 min into the reaction chamber and incubated for 1 hr. This was followed by DPBS wash for 7 min,  
22 during which the unspecific sites were blocked by flowing and incubating cell culture media for 7 min  
23 and 30 min, respectively. To measure CK-MB antigens, different concentrations of CK-MB biomarkers  
24 were flowed into the channel and incubated for 7 min and 30 min, respectively.  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47

48 **Culturing cardiospheres in the microfluidic bioreactor:** Personalized cryogenic tubes (Nalgene,  
49 Thermo Scientific) that worked as media reservoirs and bubble traps were connected between the outlet  
50 of the peristaltic pump and the inlet of the bioreactor. This system allowed sustainability of the  
51 bioreactor and long-term media sample collection without the need to interfere with the bioreactor.  
52 Media consisting of RPMI media (Sigma-Aldrich) and B27 supplement (Gibco, Life Technologies) was  
53 added. The bioreactor should also be perfused to allow for sufficient delivery/exchange of nutrients,  
54  
55  
56  
57  
58  
59  
60

1 oxygen, and waste. The spheroids mixed with 10% GelMA were cultured in the bioreactor operated  
2 with a peristaltic pump. Media was collected from the bioreactor (by changing the reservoir tube each  
3 time) on 6, 30, 78, and 126 hrs. In addition, the entire system should remain bubble-free during the  
4 culture process to avoid potential interference. After including a bubble trap and testing for 6 days, there  
5 was no evidence of leakage or bubbles in the system indicating that it could be used for long term  
6 culture of cells.


14 **Characterization of cardiac spheroids after DOX injection (Cell morphology, Beating rates):** The  
15 cardiac organoids were continuously challenged with 0, 1, and 10  $\mu$ M DOX added to the medium during  
16 perfusion culture. The beating rates of the cardiac spheroids were measured using an optical microscope  
17 (Zeiss Axio Observer D1) at desired time points for up to 140 hr. The beating rates were normalized to  
18 those at time 0 of respective samples. Three bioreactors were analyzed for each drug condition.

26 **Supporting Information Available:** Materials, Fabrication of the bioreactor, human pluripotent stem  
27 cell culture and differentiation, Characterization of functionalized microelectrodes, Live/Dead assay


36 **Acknowledgment**

40 The authors gratefully acknowledge funding from the Defense Threat Reduction Agency  
41 (DTRA) under Space and Naval Warfare Systems Center Pacific (SSC PACIFIC) Contract No. N6601-  
42 13-C-2027. The authors also acknowledge funding form the Institute for Soldier Nanotechnology,  
43 National Institutes of Health (HL092836, EB012597, AR057837, HL099073), the Office of Naval  
44 Research Young Investigator award, ONR PECASE Award. T.K. and H.A. thank Scientific and  
45 Technological Research Council of Turkey (TUBITAK). H.A. also sincerely thank Eskisehir  
46 Osmangazi University and Prof. Dr. M. Bahaddin Acat. Y.S.Z. acknowledges the National Institutes of  
47 Health National Cancer Institute Pathway to Independence Award (1K99CA201603-01A1). The

publication of this material does not constitute approval by the government of the findings or conclusions herein.




**Figure 1.** (a) Photograph of the microfabricated electrode set. (b) Schematic diagram of immobilization steps of aptamers onto the microelectrode. AFM surface characterization of (c) bare Au WE electrode, (d) antibody- and (e) aptamer-functionalized microelectrode. (f) EIS measurements after immobilization of aptamer and subsequent molecules onto bare microelectrode. (g) Normalized  $\Delta R_{ct}$  over time showing the denaturation of antibody and aptamer biosensors. The aptamer and antibody-based biosensors were fabricated on the same day and stored in PBS at 4 °C.




**Figure 2.** Nyquist curves for (a) aptamer- and (b) antibody-based sensors measured in medium.

Calibration curves for (c) aptamer- and (d) antibody-based sensors measured in PBS and medium.



**Figure 3.** (a) Photograph of the microfluidic bioreactor and the optical micrograph of the cardiac spheroids. (b) Measured normalized beating rates of cardiomyocytes over time after exposure to different concentrations (0, 1, and 10  $\mu\text{M}$ ) of DOX. (c) Live/dead assays of cardiomyocytes obtained after exposure of the cells to different concentrations of DOX up to 126 hrs. Live cells were stained green and dead cells were stained red. (Scale bar: 200  $\mu\text{m}$ ).



**Figure 4.** (a) Normalized  $R_{ct}$  values of CK-MB levels obtained using aptamer biosensors after the cardiac organoids were exposed to no-drug and 1  $\mu$ M and 10  $\mu$ M DOX for up to 126 hrs. (b) Calculated CK-MB concentrations obtained using the calibration curve. (c) Schematic illustration of the drug administration system connected to the microfluidic heart-on-a-chip bioreactor. (d) Photograph of the microfluidic bioreactor with an integrated microelectrode set. (e) Normalized  $R_{ct}$  values of CK-MB levels obtained on-chip using aptamer-based sensors after the cardiac organoids were exposed to no-drug and 1  $\mu$ M and 10  $\mu$ M of DOX for up to 126 hrs. All the functionalization and detection steps were carried on chip. (f) CK-MB concentrations versus time obtained using the calibration curve.

## REFERENCES

- (1) Hughes, J. D.; Blagg, J.; Price, D. A.; Bailey, S.; Decrescenzo, G. A.; Devraj, R. V.; Ellsworth, E.; Fobian, Y. M.; Gibbs, M. E.; Gilles, R. W.; Greene, N.; Huang, E.; Krieger-Burke, T.; Loesel, J.; Wager, T.; Whiteley, L.; Zhang, Y. *Bioorganic & medicinal chemistry letters* **2008**, *18*, 4872-4875.
- (2) Kola, I.; Landis, J. *Nat Rev Drug Discov* **2004**, *3*, 711-716.
- (3) Paul, S. M.; Mytelka, D. S.; Dunwiddie, C. T.; Persinger, C. C.; Munos, B. H.; Lindborg, S. R.; Schacht, A. L. *Nat. Rev. Drug Discov.* **2010**, *9*, 203-214.

- (4) Schiller, L. R.; Johnson, D. A. *Am J Gastroenterol* **2008**, *103*, 815-819.
- (5) Bhise, N. S.; Ribas, J.; Manoharan, V.; Zhang, Y. S.; Polini, A.; Massa, S.; Dokmeci, M. R.; Khademhosseini, A. *J. Controlled Release* **2014**, *190*, 82-93.
- (6) Zhang, Y. S.; Ribas, J.; Nadhman, A.; Aleman, J.; Selimovic, S.; Leshner-Perez, S. C.; Wang, T.; Manoharan, V.; Shin, S.-R.; Damilano, A.; Annabi, N.; Dokmeci, M. R.; Takayama, S.; Khademhosseini, A. *Lab on a Chip* **2015**, *15*, 3661-3669.
- (7) Esch, E. W.; Bahinski, A.; Huh, D. *Nat. Rev. Drug Discov.* **2015**, *14*, 248-260.
- (8) Young, E. W. K. *Integr. Biol.* **2013**, *5*, 1096-1109.
- (9) Huh, D.; Torisawa, Y.-s.; Hamilton, G. A.; Kim, H. J.; Ingber, D. E. *Lab on a Chip* **2012**, *12*, 2156-2164.
- (10) Lee, E.; Song, H. H. G.; Chen, C. S. *Current Opinion in Chemical Engineering* **2016**, *11*, 20-27.
- (11) Serena, E.; Cimetta, E.; Zatti, S.; Zaglia, T.; Zagallo, M.; Keller, G.; Elvassore, N. *PLoS One* **2012**, *7*, e48483.
- (12) Real-Fernandez, F.; Rossi, G.; Lolli, F.; Papini, A. M.; Rovero, P. *MethodsX* **2015**, *2*, 141-144.
- (13) Cappi, G.; Spiga, F. M.; Moncada, Y.; Ferretti, A.; Beyeler, M.; Bianchessi, M.; Decosterd, L.; Buclin, T.; Guiducci, C. *Anal Chem* **2015**, *87*, 5278-5285.
- (14) Sivanesan, A.; Izake, E. L.; Agoston, R.; Ayoko, G. A.; Sillence, M. *J Nanobiotechnology* **2015**, *13*, 43.
- (15) Gerszten, R. E.; Wang, T. J. *Nature* **2008**, *451*, 949-952.
- (16) Michela Casella; Antonio Dello Russo; Eleonora Russo; Ghaliyah Al-Mohani; Pasquale Santangeli; Stefania Riva; Gaetano Fassini; Massimo Moltrasio; Ester Innocenti; Daniele Colombo; Fabrizio Bologna; Gennaro Izzo; Joseph G. Gallinghouse; Luigi Di Biase; Andrea Natale; Tondo, C. *Cardiology Journal* **2014**, *Vol 21*, 516-523.
- (17) Nwankire, C. E.; Venkatanarayanan, A.; Glennon, T.; Keyes, T. E.; Forster, R. J.; Ducree, J. *Biosens Bioelectron* **2015**, *68*, 382-389.
- (18) Magliulo, M.; Mallardi, A.; Gristina, R.; Ridi, F.; Sabbatini, L.; Cioffi, N.; Palazzo, G.; Torsi, L. *Anal Chem* **2013**, *85*, 3849-3857.
- (19) McCauley, T. G.; Hamaguchi, N.; Stanton, M. *Analytical biochemistry* **2003**, *319*, 244-250.
- (20) Tombelli, S.; Minunni, M.; Mascini, M. *Biomol. Eng* **2007**, *24*, 191-200.
- (21) Kara, P.; de la Escosura-Muñiz, A.; Maltez-da Costa, M.; Guix, M.; Ozsoz, M.; Merkoçi, A. *Biosensors and Bioelectronics* **2010**, *26*, 1715-1718.
- (22) Liu, Y.; Tuleouva, N.; Ramanculov, E.; Revzin, A. *Anal Chem* **2010**, *82*, 8131-8136.
- (23) Lai, R. Y.; Plaxco, K. W.; Heeger, A. J. *Anal Chem* **2007**, *79*, 229-233.
- (24) Du, L.; Wu, C.; Peng, H.; Zou, L.; Zhao, L.; Huang, L.; Wang, P. *Sensors Actuators B: Chem.* **2013**, *187*, 481-487.
- (25) Liss, M.; Petersen, B.; Wolf, H.; Prohaska, E. *Anal Chem* **2002**, *74*, 4488-4495.
- (26) Xiao, Y.; Lubin, A. A.; Heeger, A. J.; Plaxco, K. W. *Angewandte Chemie* **2005**, *117*, 5592-5595.
- (27) Stoltenburg, R.; Reinemann, C.; Strehlitz, B. *Biomolecular engineering* **2007**, *24*, 381-403.
- (28) Ruigrok, V. J. B.; Levisson, M.; Eppink, M. H. M.; Smidt, H.; Oost, J. V. D. *Biochemical Journal* **2011**, *436*, 13.
- (29) Burbulis, I.; Yamaguchi, K.; Yu, R.; Resnekov, O.; Brent, R. *Nature Methods* **2007**, *4*, 1011-1014.
- (30) Sun, H.; Zhu, X.; Lu, P. Y.; Rosato, R. R.; Tan, W.; Zu, Y. *Molecular Therapy—Nucleic Acids* **2014**, *3*, e182.
- (31) Jayasena, S. D. *Clin. Chem.* **1999**, *45*, 1628-1650.
- (32) Hakkinen, H. *Nat Chem* **2012**, *4*, 443-455.
- (33) Xue, Y.; Li, X.; Li, H.; Zhang, W. *Nat Commun* **2014**, *5*.
- (34) Rehak, M.; Snejdarkova, M.; Otto, M. *Biosens Bioelectron* **1994**, *9*, 337-341.
- (35) Orazem, M. E.; Tribollet, B. *Electrochemical impedance spectroscopy*; John Wiley & Sons, 2011; Vol. 48.
- (36) Miodek, A.; Regan, E. M.; Bhalla, N.; Hopkins, N. A.; Goodchild, S. A.; Estrela, P. *Sensors (Basel)* **2015**, *15*, 25015-25032.

- (37) Wan, J.; Ai, J.; Zhang, Y.; Geng, X.; Gao, Q.; Cheng, Z. *Sci Rep* **2016**, *6*, 19806.
- (38) Usiskin, R. E.; Maruyama, S.; Kucharczyk, C. J.; Takeuchi, I.; Haile, S. M. *Journal of Materials Chemistry A* **2015**, *3*, 16.
- (39) Yu, X.; Lv, R.; Ma, Z.; Liu, Z.; Hao, Y.; Li, Q.; Xu, D. *Analyst* **2006**, *131*, 745-750.
- (40) Pasceri, V.; Patti, G.; Nusca, A.; Pristipino, C.; Richichi, G.; Di Sciascio, G. *Circulation* **2004**, *110*, 674-678.
- (41) Harris, B.; Nageh, T.; Marsden, J.; Thomas, M.; Sherwood, R. *Ann. Clin. Biochem.* **2000**, *37*, 764-769.
- (42) Moreira, F. T. C.; Dutra, R. A. F.; Noronha, J. P.; Sales, M. G. F. *Biosens. Bioelectron.* **2014**, *56*, 217-222.
- (43) Torabi, F.; Mobini Far, H. R.; Danielsson, B.; Khayyami, M. *Biosens. Bioelectron.* **2007**, *22*, 1218-1223.
- (44) Chon, H.; Lee, S.; Yoon, S.-Y.; Lee, E. K.; Chang, S.-I.; Choo, J. *Chem Commun* **2014**, *50*, 1058-1060.
- (45) Kim, D.-H.; Cho, I.-H.; Park, J.-N.; Paek, S.-H.; Cho, H.-M.; Paek, S.-H. *Biosensors and Bioelectronics*.
- (46) Zhang, G.-J.; Chai, K. T. C.; Luo, H. Z. H.; Huang, J. M.; Tay, I. G. K.; Lim, A. E.-J.; Je, M. *Biosens. Bioelectron.* **2012**, *35*, 218-223.
- (47) Lee, J.-O.; So, H.-M.; Jeon, E.-K.; Chang, H.; Won, K.; Kim, Y. *Anal. Bioanal. Chem.* **2008**, *390*, 1023-1032.
- (48) O'Sullivan, C. *Anal. Bioanal. Chem.* **2002**, *372*, 44-48.
- (49) Zhang, Y. S.; Aleman, J.; Arneri, A.; Bersini, S.; Piraino, F.; Shin, S. R.; Dokmeci, M. R.; Khademhosseini, A. *Biomed Mater* **2015**, *10*, 034006.
- (50) McCain, M. L.; Sheehy, S. P.; Grosberg, A.; Goss, J. A.; Parker, K. K. *Proceedings of the National Academy of Sciences* **2013**, *110*, 9770-9775.
- (51) Kim, S. B.; Bae, H.; Cha, J. M.; Moon, S. J.; Dokmeci, M. R.; Cropek, D. M.; Khademhosseini, A. *Lab Chip* **2011**, *11*, 1801-1807.
- (52) Nunes, S. S.; Miklas, J. W.; Liu, J.; Aschar-Sobbi, R.; Xiao, Y.; Zhang, B.; Jiang, J.; Masse, S.; Gagliardi, M.; Hsieh, A.; Thavandiran, N.; Laflamme, M. A.; Nanthakumar, K.; Gross, G. J.; Backx, P. H.; Keller, G.; Radisic, M. *Nat. Methods* **2013**, *10*, 781-787.
- (53) Thomas, C. A., Jr.; Springer, P. A.; Loeb, G. E.; Berwald-Netter, Y.; Okun, L. M. *Exp Cell Res* **1972**, *74*, 61-66.
- (54) Grosberg, A.; Alford, P. W.; McCain, M. L.; Parker, K. K. *Lab on a chip* **2011**, *11*, 4165-4173.
- (55) Bhise, N. S.; Manoharan, V.; Massa, S.; Tamayol, A.; Ghaderi, M.; Miscuglio, M.; Lang, Q.; Zhang, Y. S.; Shin, S. R.; Calzone, G.; Annabi, N.; Shupe, T.; Bishop, C.; Atala, A.; Dokmeci, M. R.; Khademhosseini, A. *Biofabrication* **2016**, *8*, 014101.
- (56) Fredericks, S.; Collinson, P. O.; Holt, D. W. *Clin. Chem.* **2000**, *46*, 432-435.
- (57) Saad, S. Y.; Najjar, T. A. O.; Alashari, M. *J. Biochem. Mol. Toxicol.* **2004**, *18*, 78-86.
- (58) Rosalki, S. B.; Roberts, R.; Katus, H. A.; Giannitsis, E.; Ladenson, J. H.; Apple, F. S. *Clin Chem* **2004**, *50*, 2205-2213.

For Table of Contents Only

